A new study found that Eisai and Biogen’s experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half.
Eisai’s 4523, +1.82% stock was up 1.7%% in Wednesday morning trading in Japan, while shares of Biogen Inc. BIIB, -0.17% gained 0.9% in after-hours trading on Tuesday in the U.S.
Eisai also presented the full findings from the trial on Tuesday night at the Clinical Trials on Alzheimer’s Disease annual meeting in San Francisco. A Biogen spokesperson said in a statement that the randomized, placebo-controlled, double-blind Phase 3 clinical trial shows “the promise of lecanemab as a potential new treatment option.”
The companies said deaths occurred in 0.7% and 0.8%, respectively, of the participants in the lecanemab and placebo groups, though none were related to lecanemab. There have been two reports of deaths in the trial.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focusAn experimental Alzheimer's drug slowed cognitive decline in a trial but may carry a risk of dangerous side effects for certain patients
Leer más »
New Alzheimer’s Drug Shows Positive Results but Side EffectsA new Alzheimer’s drug slowed cognitive decline in a study, but caused brain bleeds and swelling in some patients, furthering debate about its usefulness
Leer más »
Stocks making the biggest moves in the premarket: Apple, Taboola, Biogen and moreThe stocks making the biggest moves in premarket trading include Apple, Taboola, Biogen, and more.
Leer más »
Meteorite found in Somalia turns out to contain two minerals that are not found on EarthMeteorites found on Earth provide us insights into what space is made up of and how different it is from the planet we call home
Leer más »
Pennsylvania’s ‘top charitable cause’ is this, says studyA study has found the top charitable cause in each state, Pennsylvania included.
Leer más »